Sanseguokang: Recombinant anti-IL-1 humanized monoclonal antibody injection new drug application accepted for review

San Sheng Guo Jian announced that the Phase III clinical trial of the company's recombinant humanized monoclonal antibody injection for the treatment of acute gouty arthritis has achieved the primary efficacy endpoints, and has submitted a new drug application to the National Medical Products Administration and obtained approval. This drug is a newly developed anti-IL-1 antibody independently researched and developed by the company, with a completely different binding site from other products on the market targeting the same point.